发布求助
文献互助 智能选刊 最新文献

Current Opinion in Endocrine and Metabolic Research最新文献

筛选
英文 中文
Genomic landscape of anaplastic thyroid cancer and implications on therapy 癌症间变性的基因组景观及其治疗意义
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-06-01 DOI: 10.1016/j.coemr.2023.100458
Leslie Cheng, Kate Newbold
{"title":"Genomic landscape of anaplastic thyroid cancer and implications on therapy","authors":"Leslie Cheng,&nbsp;Kate Newbold","doi":"10.1016/j.coemr.2023.100458","DOIUrl":"10.1016/j.coemr.2023.100458","url":null,"abstract":"<div><p>Anaplastic thyroid cancer<span><span> (ATC) is one of the most aggressive and lethal types of cancer and treatment options remain very limited. The majority of patients present initially with </span>metastatic disease<span><span> and require systemic therapy. The shift from conventional cytotoxic therapies to more specific, </span>molecularly targeted therapies<span> is a rapidly developing phenomenon. Despite the recent success of BRAF-directed therapies, druggable mutations in ATC remain scarce and disappointing. Translational research<span> in this area is key to unlocking therapeutic options in ATC, especially as molecular testing becomes increasingly routine. Increasing number of studies in the last decade have described the genomic alterations of ATC, vastly improving our understanding of its development and evolution. In this review, we provide a snapshot of the key DNA sequencing<span> studies of ATC and their potential applications in emerging targeted therapies. We also highlight the future directions of research to tackle this devastating diagnosis.</span></span></span></span></span></p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"30 ","pages":"Article 100458"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46785259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutrient uptake and metabolism in osteoblasts 成骨细胞的营养摄取和代谢
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-06-01 DOI: 10.1016/j.coemr.2023.100447
Courtney M. Karner , Fanxin Long
{"title":"Nutrient uptake and metabolism in osteoblasts","authors":"Courtney M. Karner ,&nbsp;Fanxin Long","doi":"10.1016/j.coemr.2023.100447","DOIUrl":"10.1016/j.coemr.2023.100447","url":null,"abstract":"<div><p><span><span>Osteoblasts are the chief bone-making cells that specialize in producing and mineralizing large amounts of </span>type I collagen<span><span> and other matrix proteins. The </span>bioenergetics<span> in support of the energy-intensive osteoblast activity is not well understood but has gained renewed interest in recent years. Research in the past ten years has not only confirmed glucose as the main energy substrate for osteoblasts, but also identified contributions of amino acids and fatty acids to either bioenergetic or biosynthetic processes in the cell. Moreover, osteogenic signals have been functionally linked to </span></span></span>substrate utilization in osteoblasts. The brief review aims to summarize the recent findings, and to identify remaining questions in the emerging field.</p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"30 ","pages":"Article 100447"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46130315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial board page 编委会页面
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-04-01 DOI: 10.1016/S2451-9650(23)00018-2
{"title":"Editorial board page","authors":"","doi":"10.1016/S2451-9650(23)00018-2","DOIUrl":"https://doi.org/10.1016/S2451-9650(23)00018-2","url":null,"abstract":"","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"29 ","pages":"Article 100451"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50192774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone mineralisation and glucose metabolism 骨矿化和葡萄糖代谢
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-04-01 DOI: 10.1016/j.coemr.2023.100446
Fiona L. Roberts , Vicky E. MacRae
{"title":"Bone mineralisation and glucose metabolism","authors":"Fiona L. Roberts ,&nbsp;Vicky E. MacRae","doi":"10.1016/j.coemr.2023.100446","DOIUrl":"10.1016/j.coemr.2023.100446","url":null,"abstract":"<div><p>Recent advancements in the bone biology field have identified a novel bone-metabolism axis. In this review, we highlight several novel studies that further our knowledge of new endocrine functions of bone; explore remaining unanswered questions; and discuss translational challenges in this complex era of bone biology research.</p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"29 ","pages":"Article 100446"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41390103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erythropoietin and skeletal cells crosstalks in physiology and disease 促红细胞生成素和骨骼细胞在生理和疾病中的交叉作用
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-04-01 DOI: 10.1016/j.coemr.2023.100436
Giulia Lanzolla , Mohd Parvez Khan , Elena Sabini , Amato Giaccia , Ernestina Schipani
{"title":"Erythropoietin and skeletal cells crosstalks in physiology and disease","authors":"Giulia Lanzolla ,&nbsp;Mohd Parvez Khan ,&nbsp;Elena Sabini ,&nbsp;Amato Giaccia ,&nbsp;Ernestina Schipani","doi":"10.1016/j.coemr.2023.100436","DOIUrl":"10.1016/j.coemr.2023.100436","url":null,"abstract":"<div><p><span>The hypoxia-inducible factor 2alpha (HIF-2), which is a member of the HIF family of transcription factors and a critical component of the hypoxia-driven pathway, regulates adult erythropoiesis through the renal production and secretion of </span>erythropoietin<span><span> (EPO). Notably, circulating EPO also affects bone mass through either direct or indirect actions on osteoblastic and osteoclastic cells. Adding complexity to the picture, we have recently reported that osteoblastic cells produce and secrete EPO upon activation of HIF-2. Although physiological role of osteoblastic EPO in controlling hematopoiesis remains to be determined, our findings could have translational implications for the </span>treatment of anemia.</span></p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"29 ","pages":"Article 100436"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43327511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Recent basic and clinical findings concerning FGF23: A bone-derived hormone FGF23，一种骨源性激素的最新基础和临床发现
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-04-01 DOI: 10.1016/j.coemr.2023.100445
Seiji Fukumoto
{"title":"Recent basic and clinical findings concerning FGF23: A bone-derived hormone","authors":"Seiji Fukumoto","doi":"10.1016/j.coemr.2023.100445","DOIUrl":"10.1016/j.coemr.2023.100445","url":null,"abstract":"<div><p><span>FGF23<span> is essential for the regulation of serum phosphate level and the aberrant actions of FGF23 cause hypophosphatemic or hyperphosphatemic </span></span>diseases<span>. The objective of this review is to provide a current and relevant summary of the recent basic and clinical findings concerning FGF23. Recent findings: Many factors have been shown to affect FGF23 production while the precise roles of these factors in phosphate metabolism are largely unknown. Anti-FGF23 antibody has become clinically available, and the efficacy of this antibody has been reported in several hypophosphatemic diseases caused by excessive actions of FGF23.Summary: The identification of FGF23 came to the development of a new therapy for hypophosphatemic diseases. Still, there are many unanswered questions concerning FGF23.</span></p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"29 ","pages":"Article 100445"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45932922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endocrine functions of sclerostin 硬化素的内分泌功能
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-02-01 DOI: 10.1016/j.coemr.2022.100433
Ryan C. Riddle
{"title":"Endocrine functions of sclerostin","authors":"Ryan C. Riddle","doi":"10.1016/j.coemr.2022.100433","DOIUrl":"10.1016/j.coemr.2022.100433","url":null,"abstract":"<div><p>Sclerostin, the product of the <em>SOST</em> gene has primarily been studied for its profound impact on bone mass. By interacting with LRP5 and LRP6, the glycoprotein suppresses the propagation of Wnt signals to β-catenin and thereby suppresses new bone formation. In this review, we discuss emerging data which suggest that sclerostin also acts outside the skeleton to influence metabolism. In humans, serum sclerostin levels are associated with body mass index and indices of metabolic function. Likewise, genetic mouse models of <em>Sost</em> gene deficiency indicate sclerostin influences adipocyte development and insulin signaling. These data raise the possibility that sclerostin neutralization may be effective at treating two epidemic conditions: osteoporosis and obesity.</p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"28 ","pages":"Article 100433"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881182/pdf/nihms-1859916.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9169542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Premature ovarian insufficiency 卵巢早衰
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-02-01 DOI: 10.1016/j.coemr.2023.100435
Ekta Kapoor
{"title":"Premature ovarian insufficiency","authors":"Ekta Kapoor","doi":"10.1016/j.coemr.2023.100435","DOIUrl":"10.1016/j.coemr.2023.100435","url":null,"abstract":"<div><p><span>Natural menopause typically occurs between the ages of 46–55 years. Premature ovarian insufficiency<span> or premature menopause<span> results from compromised ovarian follicular activity, occurring spontaneously or because of medical interventions, prior to the age of 40 years. The premature loss of estrogen leads to bothersome menopause symptoms and predisposes the women to multiple long-term health risks including a higher mortality risk. Hormone replacement therapy used until the natural age of menopause can help manage the symptoms effectively, and can mitigate the long-term risk of estrogen deprivation. However, hormone replacement therapy is underutilized in this population due to the inappropriate extrapolation of potential risks observed with </span></span></span>hormone therapy use in women after natural menopause. There is a large unmet need for educating patients and providers regarding the impact of premature ovarian insufficiency and its appropriate management.</p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"28 ","pages":"Article 100435"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9145858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How preclinical models of menopause can inform clinical care: A focus on midlife and reciprocal communication between clinical and preclinical science 更年期的临床前模型如何指导临床护理:关注中年和临床与临床前科学的相互交流
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-02-01 DOI: 10.1016/j.coemr.2023.100434
Heather A. Bimonte-Nelson , Victoria E. Bernaud
{"title":"How preclinical models of menopause can inform clinical care: A focus on midlife and reciprocal communication between clinical and preclinical science","authors":"Heather A. Bimonte-Nelson ,&nbsp;Victoria E. Bernaud","doi":"10.1016/j.coemr.2023.100434","DOIUrl":"10.1016/j.coemr.2023.100434","url":null,"abstract":"<div><p>Midlife in women typically includes the menopausal transition<span>, a time of hormonal transformation, adaptation, and reorganization. Coincident with this dynamic period of physiological change, there are putatively modifiable factors that influence disease, short-term and long-term health outcomes, symptom emergence, and longevity. The menopause transition could be considered a window of vulnerability; however, it is also a window of opportunity for intervention. Thus, the menopause transition is a critical sensitive window whereby there is opportunity for turning points for healthy aging trajectories. Preclinical research can aid in this pursuit of scientific discovery for modifiable factors and treatments, and their particular parameters. Rodent menopause models include surgical and transitional variations, allowing detection of precise determinants impacting menopause-related outcomes. These models permit systematic manipulation of endogenous and exogenous hormone exposures across the lifespan, with infinite outcome measurements ranging from molecular to behavioral. This research is uniquely poised to address complex, interactive hypotheses with extensive control in a relatively short timeframe, including dissociation of age and menopause effects. To understand the many dynamic changes with menopause, iterative and reciprocal communication between clinical and preclinical domains of science is key.</span></p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"28 ","pages":"Article 100434"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46112513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial board page 编委会页面
Current Opinion in Endocrine and Metabolic Research Pub Date : 2023-02-01 DOI: 10.1016/S2451-9650(23)00006-6
{"title":"Editorial board page","authors":"","doi":"10.1016/S2451-9650(23)00006-6","DOIUrl":"https://doi.org/10.1016/S2451-9650(23)00006-6","url":null,"abstract":"","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"28 ","pages":"Article 100439"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50171578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信